The coagulation cascade - Clinical implications;Die gerinnungskaskade - Mechanismen und klinische implikationen

Herz

Volumn 30, Issue 3, 2005, Pages 170-175

  Langer, Harald ^a   Gawaz, Meinrad ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Coagulation; Heparin; Low molecular weight heparin; PCI

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; CERTOPARIN; DABIGATRAN; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRUDIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RAZAXABAN; REVIPARIN; RIVAROXABAN; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLOOD CLOTTING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FIBRIN FORMATION; HEMOSTASIS; HUMAN; ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; THROMBOCYTE; THROMBUS;

ANTICOAGULANTS; BLOOD COAGULATION; FIBRIN; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 20044384895     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-005-2691-8     Document Type: Review

References (40)

1. Gawaz M, Seyfarth M, Muller I, et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol 2001;87:332-6, A9.
2. Gawaz M, Muller I, Besta F. Combined antithrombotic therapy for acute coronary syndrome. Semin Vasc Med 2003;3:163-76.
3. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
4. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
5. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999;341:319-27.
6. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
7. Hoppensteadt D, Walenga JM, Fareed J, et al. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am 2003;17:313-41.
8. Altman R, Scazziota A, Rouvier J. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor. Haemostasis 1998;28:229-35.
9. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
10. Hirsh J, Siragusa S, Cosmi B, et al. Low molecular weight heparins (LM-WH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995;74:360-3.
11. Bowers J, Ferguson JJ III. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol 1994;17:357-61.
12. Dougherty KG, Gaos CM, Bush HS, et al. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992;26:260-3.
13. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-71.
14. Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003;146:628-34.
15. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-6.
16. Boccara A, Benamer H, Juliard JM, et al. A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J 1997;18:631-5.
17. Koch KT, Piek JJ, de Winter RJ, et al. Early ambulation after coronary angioplasty and stenting with six French guiding catheters and low-dose heparin. Am J Cardiol 1997;80:1084-6.
18. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and ThrombolyticTherapy. Chest 2004;126:576S-99S.
19. Ellis SG, Roubin GS, Wilentz J, et al. Effect of 18-to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-82.
20. Friedman HZ, Cragg DR, Glazier SM, et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994;24:1214-9.
21. Brack MJ, Ray S, Chauhan A, et al. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome. J Am Coll Cardiol 1995;26:947-54.
22. Cosmi B, Fredenburgh JC, Rischke J, et al. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation 1997;95:118-24.
23. Marbet GA. [Heparins.] Ther Umsch 2003;60:10-3.
24. Altman R, Scazziota A, Rouvier J. Daily 50 mg or 500 mg aspirin does not affect the cooperation of arachidonic acid and ADP on platelet aggregation. Circulation 1998;97:118-9.
25. Haas S, Haas P. Niedermolekulares Heparin. In: Haas, S, Haas P, Hrsg. Niedermolekulare Heparine - die Anwendung in Klinik und Praxis. Steinen: Zett, 1999.
26. Arjomand H, Surabhi SK, Cohen M. Unfractionated versus fractionated heparin for percutaneous coronary intervention. Curr Cardiol Rep 2002;4:327-33.
27. Brieger D, Solanki V, Gaynor M, et al. Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes. Am J Cardiol 2002;89:1167-70.
28. Grines CL. Anticoagulation requirements for coronary interventions and the role of low molecular weight heparins. J Invasive Cardiol 1999;11:Suppl A:7A-12A.
29. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneouscoronary intervention: an expert consensus. Am Heart J 2002;144:615-24.
30. Preisack MB, Bonan R, Meisner C, et al. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial). Eur Heart J 1998;19:1232-8.
31. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-5.
32. Miller L, Gupta A, Bertolet BD. Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. J Invasive Cardiol 2002;14:247-50.
33. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneouscoronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol 2000;12:Suppl E:E14-8. discussion E25-8.
34. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003;41:20-5.
35. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:470-7.
36. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-52.
37. Berger PB, Mahaffey KW, Meier SJ, et al. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J 2002;143:841-6.
38. Amann FW, Neuenschwander C, Meyer BJ. Fraxiparin for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Hemost 1993;19 Suppl 1:160-3.
39. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) trial. Circulation 1994;90:908-14.
40. Lablanche JM, McFadden EP, Meneveau N, et al. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastic Coronaire Transluminale. Circulation 1997;96:3396-402.